Joel Greenblatt’s Palvella Therapeutics PVLA Stock Holding History

Joel Greenblatt’s Portfolio PVLA Stock Details PVLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-458	Closed	-$250K	–	1064
2018 Q1	$250K	Buy	+458	New	+$284K	﹤0.01%	854

Other funds holding PVLA

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

TCM

Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return

ACM

Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

Joel Greenblatt's PVLA Position: Q2 2018 in Review

Joel Greenblatt sold out of Palvella Therapeutics (PVLA) in Q2 2018, closing a stake of 458 shares — an estimated $250K sold.

Joel Greenblatt first reported a position in PVLA in Q1 2018 and held it in 1 quarter. The position peaked at $250K in Q1 2018. 115 funds tracked by Wall St. Rank hold PVLA as of Q2 2018.

Joel Greenblatt reported no remaining Palvella Therapeutics position as of Q2 2018 after selling out during the quarter.
Joel Greenblatt sold 458 Palvella Therapeutics shares in Q2 2018, an estimated $250K.
Joel Greenblatt first reported a position in Palvella Therapeutics in Q1 2018 and held it in 1 quarter.
Joel Greenblatt's Palvella Therapeutics position peaked at $250K in Q1 2018.
115 funds tracked by Wall St. Rank held Palvella Therapeutics as of Q2 2018.

Based on Gotham Asset Management's 13F filing for Q2 2018, filed 14 Aug 2018.